Bedrocan

Introduced in 2003, Bedrocan® is  the brand name for the cultivar Cannabis sativa L. ‘Afina’. Cannabis sativa L. ‘Afina’ is the first cultivar developed and it features 22% THC, with a CBD-level below 1%. It’s the most widely used medicinal cannabis product and has been use...

Introduced in 2011, Bedica® is the brand name for the indica cultivar Cannabis sativa L. ‘Talea’. Cannabis sativa L. ‘Talea’ was developed in response to mounting evidence of a real difference in the effects of sativa and indica types. Characteristic differences between ...

Introduced in 2005, Bedrobinol® is the brand name for the cultivar Cannabis sativa L. ‘Ludina’. Cannabis sativa L. ‘Ludina’ is bred in-house by Bedrocan. Its THC-level can be considered medium strength, standardised at 13,5%, with a CBD-level below 1 %. Bedrobinol® is availab...

Bedrocan has developed a new practice for medicinal cannabis cultivation. The practice is already in use at Bedrocan’s facilities and is called GMCCP: Good Medicinal Cannabis Cultivation Practice. According to Bedrocan, GACP is not sufficient for cannabis intended for medicinal use, hence the need for a special practice for the cultivation of medicinal cannabis.

Monique van Velzen is research manager, assistant professor and supervisor of medical researchers at the Anesthesiology department of the LUMC in Leiden, Netherlands. Her research focuses on understanding patients with (chronic) pain better and studying the most optimal form of pain relief. Since 2017, Monique has been supervising research into medicinal cannabis for specific types of pain. For more information about the webinars, visit www.bedrocan.com/series